Merkel cell carcinoma (MCC) is recognized by its morphologic features and by its classic immunophenotypic properties. Although MCCs demonstrating nonclassic immunoreactivities have been described, a case documenting a change in immunophenotype during the course of disease progression has not been previously reported. We report a case of MCC that initially demonstrated cytokeratin 20 positivity but lost expression in subsequent metastases. Likewise, thyroid transcription factor-1 was initially negative in the tumor but expression was present in metastatic lesions.
INTRODUCTION
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin with aggressive behavior and a rising incidence. Characteristically, MCC is positive for cytokeratin 20 (CK20) and negative for thyroid transcription factor-1 (TTF-1). Although CK20 negative primary MCCs or TTF-1 positive MCCs have been described, the loss of CK20 and simultaneous acquisition of TTF-1 expression in metastatic MCC has not been reported. 1, 2 
CASE REPORT
A 68-year-old white immunocompetent man with a history of squamous cell carcinoma of the tongue in remission presented with a primary MCC on the left frontal scalp in 2006, which was treated with surgery and radiation therapy at that time. He then developed recurrent MCC on the forehead and scalp in 2007, and subsequent metastasis to a neck lymph node in 2008. The patient underwent multiple surgeries and radiation for these recurrent tumors. In 2012, he was found to have a solitary left frontal brain metastasis and was treated with a gross total surgical resection followed by intensitymodulated radiation therapy with 15 Gy delivered to the resection cavity and margin in a single fraction. However, biopsy-proven tumor recurred in the same region of the brain early in 2013, along with an additional new metastatic left frontal dural-based lesion not in continuity with the previously seen lesion or craniotomy site. He was no longer a surgical candidate and elected to be in hospice. Multiple imaging studies failed to demonstrate other primary lesions.
Histologic examination of the primary tumor demonstrated neuroendocrine morphology, and characteristic paranuclear accentuation of CK20 immunoreactivity. The tumor cells were negative for TTF-1 (Fig. 1C ). Interestingly, in the 2012 brain metastasis, only a few CK20 positive tumor cells were identified, while CK20 expression was completely lost in the brain tumor recurrent in 2013 ( Fig. 1E and H). Conversely, TTF-1 positivity was detected in the patient's 2012 brain metastasis and was diffusely positive in brain tumor biopsied in 2013 ( Fig. 1F and I) . CK7 was negative in both the primary and metastatic brain tumors (data not shown). Based on the known history of MCC and the absence of other malignancy, the findings were believed to be compatible with metastatic MCC with an unusual immunohistochemical pattern.
DISCUSSION
CK20 is an intermediate filament and is expressed in the gastrointestinal epithelial cells and in epidermal Merkel cells. TTF-1 is a nuclear transcriptional factor expressed in epithelial cells of the thyroid and lung. Antibodies to CK20 and TTF-1 are frequently used in the workup of cutaneous neuroendocrine carcinomas to help differentiate MCC (CK20 positive, TTF-1 negative) from metastatic small-cell lung carcinoma (CK20 negative, TTF-1 positive). CK20 negative primary MCCs have been described, in which case the diagnosis rests on an expanded battery of immunohistochemical markers coupled with clinical and radiographic exclusion of a neuroendocrine carcinoma arising from another organ. 3 However, expression patterns of CK20 in metastatic MCCs have not been evaluated. Likewise, negative TTF-1 has been considered to have a high specificity in differentiating MCC from small-cell carcinomas of lung origin. However, 2 recent studies have demonstrated TTF-1 positivity in 4 of 65 cases of MCCs. 4 Similarly, Sierakowski et al 1 described a case with TTF-1 positivity in both primary and lymph node metastatic tumors. Moreover, a CK20 negative primary MCC with TTF-1 positivity is reported. 2 Nevertheless, this altered expression pattern of CK20 and TTF-1 in the brain metastases The patient's primary tumor showed cords and nests of tumor cells with a high nuclear:cytoplasm ratio infiltrating through dermal collagen (A). The tumor cells showed CK20 positivity, demonstrating areas with paranuclear accentuation (B). The tumor cells were negative for TTF-1 (C). Examination of the brain metastases in 2012 showed a cellular tumor with neuroendocrine features (D). Focal CK20 expression was detected (E) with patchy areas of strong nuclear TTF-1 expression (F). Recurrence of brain metastases in 2013 showed a cellular tumor (G) with an absence of CK20 expression (H) and diffuse nuclear TTF-1 expression (I).
of MCC as seen in our patient has never been reported. The etiology and clinical significance remains to be elucidated. Whether it coincides with epithelial-mesenchymal transition or is a result of radiation therapy needs further investigation.
